Delaram Safarpour1, Dylan P Thibault1, Cori L DeSanto1, Cynthia M Boyd1, E Ray Dorsey1, Brad A Racette1, Allison W Willis2. 1. From the Departments of Neurology (D.S., D.P.T., A.W.W.) and Biostatistics and Epidemiology (A.W.W.), Center for Clinical Epidemiology and Biostatistics (D.S., A.W.W.), and Leonard Davis Institute of Health Economics (A.W.W.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Department of Neurology (C.L.D., B.A.R.), Washington University School of Medicine, St. Louis, MO; Departments of Medicine (C.M.B.) and Health Policy and Management (C.M.B.), Johns Hopkins School of Medicine, Baltimore, MD; Department of Neurology (E.R.D.), Center of Human Experimental Therapeutics, University of Rochester Medical Center, NY; and School of Public Health (B.A.R.), Faculty of Health Sciences, University of the Witwatersrand, Parktown, South Africa. 2. From the Departments of Neurology (D.S., D.P.T., A.W.W.) and Biostatistics and Epidemiology (A.W.W.), Center for Clinical Epidemiology and Biostatistics (D.S., A.W.W.), and Leonard Davis Institute of Health Economics (A.W.W.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Department of Neurology (C.L.D., B.A.R.), Washington University School of Medicine, St. Louis, MO; Departments of Medicine (C.M.B.) and Health Policy and Management (C.M.B.), Johns Hopkins School of Medicine, Baltimore, MD; Department of Neurology (E.R.D.), Center of Human Experimental Therapeutics, University of Rochester Medical Center, NY; and School of Public Health (B.A.R.), Faculty of Health Sciences, University of the Witwatersrand, Parktown, South Africa. allison.willis@uphs.upenn.edu.
Abstract
OBJECTIVE: To examine long-term care facility (LTCF or nursing home) use and end-of-life care for individuals with Parkinson disease (PD). METHODS: In this nationwide retrospective cohort study, we compared LTCF and hospice utilization among Medicare beneficiaries diagnosed with PD by demographic, clinical, and physician characteristics. We also examined the impact of outpatient neurologist care for institutionalized patients with PD on end-of-life care. RESULTS: We identified 469,055 individuals with PD who received Medicare benefits in 2002. Nearly 25% (more than 100,000 in total) resided in an LTCF. Women with PD had greater odds of nursing facility residence (adjusted odds ratio [AOR] 1.34, 95% confidence interval [CI] 1.30-1.38) compared with men. Black individuals with PD were 34% more likely than white individuals to reside in an LTCF (AOR 1.34, 95% CI 1.30-1.38), contrary to the race patterns typically observed for LTCF use. Hip fracture (AOR 2.10, 95% CI 2.04-2.15) and dementia (AOR 4.06, 95% CI 4.00-4.12) were the strongest clinical predictors of LTCF placement. Only 33% (n = 38,334) of nursing home residents with PD had outpatient neurologist care. Eighty-four percent (n = 80,877) of LTCF residents with PD died by December 31, 2005. Hospice utilization varied little by race and sex. LTCF residents who had outpatient neurologist care were twice as likely to utilize hospice services before death (AOR 2.35, 95% CI 2.24-2.47). CONCLUSIONS AND RELEVANCE: A large proportion of the Medicare PD population resides in an LTCF. There is substantial unmet need for palliative care in the PD population. Increased efforts to provide specialist care to dependent individuals with PD may improve end-of-life care.
OBJECTIVE: To examine long-term care facility (LTCF or nursing home) use and end-of-life care for individuals with Parkinson disease (PD). METHODS: In this nationwide retrospective cohort study, we compared LTCF and hospice utilization among Medicare beneficiaries diagnosed with PD by demographic, clinical, and physician characteristics. We also examined the impact of outpatient neurologist care for institutionalized patients with PD on end-of-life care. RESULTS: We identified 469,055 individuals with PD who received Medicare benefits in 2002. Nearly 25% (more than 100,000 in total) resided in an LTCF. Women with PD had greater odds of nursing facility residence (adjusted odds ratio [AOR] 1.34, 95% confidence interval [CI] 1.30-1.38) compared with men. Black individuals with PD were 34% more likely than white individuals to reside in an LTCF (AOR 1.34, 95% CI 1.30-1.38), contrary to the race patterns typically observed for LTCF use. Hip fracture (AOR 2.10, 95% CI 2.04-2.15) and dementia (AOR 4.06, 95% CI 4.00-4.12) were the strongest clinical predictors of LTCF placement. Only 33% (n = 38,334) of nursing home residents with PD had outpatient neurologist care. Eighty-four percent (n = 80,877) of LTCF residents with PD died by December 31, 2005. Hospice utilization varied little by race and sex. LTCF residents who had outpatient neurologist care were twice as likely to utilize hospice services before death (AOR 2.35, 95% CI 2.24-2.47). CONCLUSIONS AND RELEVANCE: A large proportion of the Medicare PD population resides in an LTCF. There is substantial unmet need for palliative care in the PD population. Increased efforts to provide specialist care to dependent individuals with PD may improve end-of-life care.
Authors: Elizabeth A McGlynn; Steven M Asch; John Adams; Joan Keesey; Jennifer Hicks; Alison DeCristofaro; Eve A Kerr Journal: N Engl J Med Date: 2003-06-26 Impact factor: 91.245
Authors: Allison W Willis; Mario Schootman; Nathan Kung; Xiao-Yu Wang; Joel S Perlmutter; Brad A Racette Journal: Neurology Date: 2013-12-11 Impact factor: 9.910
Authors: D Weintraub; A Raskin; P E Ruskin; A L Gruber-Baldini; S I Zimmerman; J R Hebel; P German; J Magaziner Journal: Psychiatr Serv Date: 2000-10 Impact factor: 3.084
Authors: Michelle E Fullard; Dylan P Thibault; Veronica Todaro; Susan Foster; Lori Katz; Robin Morgan; Drew S Kern; Jason M Schwalb; Enrique Urrea Mendoza; Nabila Dahodwala; Lisa Shulman; Allison W Willis Journal: Parkinsonism Relat Disord Date: 2017-12-14 Impact factor: 4.891
Authors: E Ray Dorsey; Floris P Vlaanderen; Lucien Jlpg Engelen; Karl Kieburtz; William Zhu; Kevin M Biglan; Marjan J Faber; Bastiaan R Bloem Journal: Mov Disord Date: 2016-08-08 Impact factor: 10.338